229 related articles for article (PubMed ID: 23815519)
1. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
Kanellopoulou T; Alexopoulou A
Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
[TBL] [Abstract][Full Text] [Related]
3. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
5. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
[TBL] [Abstract][Full Text] [Related]
6. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
7. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
8. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Karnezis TT; Davidson TM
Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
[TBL] [Abstract][Full Text] [Related]
10. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Chen S; Karnezis T; Davidson TM
Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L
Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
Karnezis TT; Davidson TM
Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
[TBL] [Abstract][Full Text] [Related]
14. Hereditary hemorrhagic telangiectasia/avastin.
Davidson TM; Olitsky SE; Wei JL
Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
[TBL] [Abstract][Full Text] [Related]
15. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
Simonds J; Miller F; Mandel J; Davidson TM
Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
[TBL] [Abstract][Full Text] [Related]
17. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
18. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
Arizmendez NP; Rudmik L; Poetker DM
Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
[TBL] [Abstract][Full Text] [Related]
20. Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.
Lacout A; Marcy PY; El Hajjam M; Lacombe P
Med Hypotheses; 2012 Nov; 79(5):605-6. PubMed ID: 22959314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
